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BACKGROUND/PURPOSE: Sphingomonas paucimobilis is a glucose-nonfermenting Gram-negative bacil-
lus that is widely distributed in both natural environment and hospitals. Various infections in humans 
have been reported, but most have been limited to sporadic case reports. The aim of this study was to 
describe the clinical characteristics and manifestations of S. paucimobilis bacteremia. We also reviewed the 
literature on S. paucimobilis bacteremia.
METHODS: Cases of S. paucimobilis bacteremia were identified retrospectively at a university-affiliated 
hospital in Taiwan. In addition, relevant case reports were identified through PubMed and reviewed.
RESULTS: From April 2004 to April 2008, 42 cases of S. paucimobilis bacteremia were identified in this 
study. Among them, 16 cases were identified from E-Da hospital, Kaohsiung, Taiwan and 26 cases from 
the literature review. The median age of patients was 48.5 years and 57.1% were male. The most common 
comorbidities included malignancy (57.1%), immunosuppressant use (40.5%), and diabetic mellitus (11.9%). 
Hospital-acquired bacteremia accounted for 69.0% of infections. Primary bacteremia and catheter-related 
bloodstream infection were found in 35.7% and 33.3% respectively. The most effective antibiotics were 
fluoroquinolones, carbapenems, and β-lactam/β-lactamase inhibitor combinations. All 42 patients sur-
vived the S. paucimobilis bacteremic episodes, but three patients experienced septic shock.
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CONCLUSION: S. paucimobilis can cause infections in healthy as well as immunocompromised individuals. 
Although it is an organism of low clinical virulence, infection caused by S. paucimobilis can lead to septic 
shock. Further clinical research is required to characterize this infection.
KEYWORDS: antibiotic treatment, bacteremia, septic shock, Sphingomonas paucimobilis
of patients with positive blood cultures for S. paucimobilis 
were reviewed. Only patients with notable infections, such 
as fever, leukocytosis, or other laboratory findings evi-
denced by radiographic, surgical, or clinical findings, were 
included in this study. Demographic and clinical data 
were collected, including age, gender, underlying diseases, 
vital signs, indwelling intravenous devices, antimicrobial 
chemotherapy, and clinical outcomes.
Definition of bacteremia
Hospital-acquired bacteremia was defined by at least one 
positive blood culture for S. paucimobilis taken at least 
72 hours after admission in patients without clinical evi-
dence of septicemia on presentation. Community-acquired 
bacteremia was defined in patients that developed bacter-
emia within 72 hours of hospitalization. The source of 
bacteremia was determined on the basis of clinical findings 
or bacterial culture results. Bacteremic episodes without 
concurrent infectious foci were considered as primary 
bacteremia. Types of indwelling intravascular devices in-
cluded the central venous pressure catheter, Hemo-Cath, 
Port-A-Cath, Hickman catheter, Dacron graft, Groshong 
catheter, and arterial line. Catheter-related bacteremia was 
diagnosed according to the standard definitions of catheter-
related infections: (1) isolation of the same microorgan-
ism from blood and exudates from the catheter exit site or 
specimens from the catheter lumen in the presence of signs 
of inflammation; and (2) isolation of the same microor-
ganism from blood and the catheter tip on removal of the 
catheter.29 Shock was defined as systolic blood pressure 
< 90 mmHg or requiring inotropic agents to maintain 
blood pressure. Immunosuppressant use was defined as 
the utilization of cytotoxic agents for cancer, before bone 
marrow transplantation, or the use of corticosteroids 
(> 30 mg prednisolone daily or 1 week). We defined antibi-
otic therapy as inappropriate if an antibiotic agent active 
against S. paucimobilis (as determined by in vitro suscep-
tibility testing) at the usual recommended dosage was 
Introduction
Sphingomonas paucimobilis, formerly known as Pseudomonas 
paucimobilis, is a yellow-pigmented, glucose-nonfermenting, 
strictly aerobic, Gram-negative bacillus with a single polar 
flagellum. It is categorized as CDC group IIk biotype 1,1 and 
it was initially reported to be a human pathogen in 1979.2–4 
The natural habitat of this organism has not been fully 
defined but it is known to be widely distributed in the 
natural environment, particularly in water and soil, and 
has also been isolated from hospital settings, including 
hospital water systems, distilled water, dialysis fluid, 
nebulizers, and other respiratory therapy equipment.5–8 
S. paucimobilis has been associated with a variety of infections 
in humans, including bacteremia, pneumonia, catheter-
related infections, meningitis, peritonitis, osteomyelitis, 
septic arthritis, postoperative endophthalmitis, lung em-
pyema, splenic abscesses, urinary tract infections, and bil-
iary tract infections.3,4,9–28
S. paucimobilis bacteremia occurs infrequently, but it 
has been encountered with increasing frequency in clin-
ical settings. The only current publications discussing 
S. paucimobilis bacteremia are either isolated case reports 
or short series reports. In this study, we analyzed the clini-
cal characteristics, manifestations, treatment, and clinical 
outcome of patients with S. paucimobilis bacteremia, iden-
tified both from E-Da hospital, Kaohsiung, Taiwan and 
the literature review. To the best of our knowledge, this is 
the largest case study of S. paucimobilis bacteremia to date.
Methods
Patient identification
This retrospective study was conducted at the E-Da hospi-
tal, a 1,000-bed hospital affiliated to I-Shou University in 
Southern Taiwan, and has been approved by the institu-
tional review board of E-Da hospital (No. EMRP-097-
026). From April 2004 to April 2008, the medical records 
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not administered during the 48 hours after diagnosis of 
infection.
Microbiology on blood culture samples
Blood culture samples were processed by the BACTEC 
9240 system (Becton Dickinson, Sparks, MD, USA). All 
positive cultures were Gram-stained and subcultured on 
blood agar and eosin-methylene blue agar plates for fur-
ther identification. Identification of S. paucimobilis was 
performed on the ID 32 GN (bioMérieux, Marcy L’etoile, 
France) or Phoenix-100 ID/AST (Becton Dickinson) auto-
mated system. All S. paucimobilis isolates were tested for 
antibiotic susceptibility by the standard disk diffusion 
method. Because there are no standards for the suscepti-
bility test for S. paucimobilis, the zone diameter interpretive 
standards were applied as described for the glucose-
nonfermenting bacilli Acinetobacter spp. according to the 
criteria of Clinical and Laboratory Standards Institute 
(formerly the National Committee for Clinical Laboratory 
Standards).30
Review of the literature
A literature search was initiated through PubMed (National 
Library of Medicine, Bethesda, MD, USA; database from 
January 1966 through April 2008) using the following 
key words: Sphingomonas paucimobilis or Pseudomonas 
paucimobilis. Only bacteremic patients were enrolled in 
our study. The demographic data, clinical characteris-
tics, manifestations, treatments, and clinical outcomes 
were collected for further analysis.
Results
A total of 16 patients who had positive blood cultures 
for S. paucimobilis were identified from our hospital dur-
ing the study period. The median age of the patients 
was 54.0 years (range, 5 month–87 years; Table 1). In 
the literature search, 26 patients with S. paucimobilis bac-
teremia were identified. The median age of patients was 
45.5 years (range, 10 days–82 years; Table 2).3,4,9–21 Two 
cases were reported before 1980, two from 1981 to 1990, 
Table 1. Clinical characteristics and manifestations of 16 survived patients with Sphingomonas paucimobilis bacteremia
Case Age Sex
 Infectious Underlying Acquired Intravascular 
Antibiotics
   foci conditions source devices
 1 45 yr M SSTI Oral cancer Community – Cefazolin, gentamicin
 2 77 yr M SSTI HCC, LC Community – Amoxicillin/clavulanate
 3 70 yr F BTI Klatskin tumor, DM Hospital – Piperacillin, gentamicin
 4a 77 yr M Primary DM, LC, ESRD, HCC Hospital Hemo-Cath Ceftazidime
 5 52 yr F CR-BSI Colon cancer Hospital Port-A-Cath Cefoxitin
 6 18 yr F UTI ESRD, schizophrenia Hospital Hemo-Cath Cefazolin
 7 62 yr F Primary Ureteral stone Community – Cefuroxime
 8 87 yr F Primary Radial fracture, DM Hospital – Cefuroxime, gentamicin
 9 5 yr M Pneumonia – Community – Ampicillin/sulbactam
10 56 yr F CR-BSI Colon cancer, COPD, Hospital Port-A-Cath Cefotaxime, gentamicin
    chronic steroid use
11 60 yr F Primary DM, chronic steroid use Hospital – Ceftazidime
12 76 yr F Pneumonia Chronic steroid use Hospital – Ceftazidime
13 48 yr M SSTI Hypopharyngeal cancer Hospital – Piperacillin, amikacin
14 49 yr M CR-BSI Oral cancer, HCC, LC, DM Hospital Port-A-Cath Cefazolin, gentamicin
15 5 mo M UTI – Community – Ampicillin, gentamicin
16 43 yr M Primary Esophageal cancer, Community Port-A-Cath Cefazolin, gentamicin
    alcoholism
aPatient presented with septic shock. SSTI = skin and soft tissue infection; HCC = hepatocellular carcinoma; LC = liver cirrhosis; BTI = biliary 
tract infection; DM = diabetes mellitus; ESRD = end-stage renal disease; CR-BSI = catheter-related bloodstream infection; UTI = urinary tract 
infection; COPD = chronic obstructive pulmonary disease.
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Table 2. Clinical characteristics and manifestations of 26 survived patients with Sphingomonas paucimobilis bacteremia from the 
literature review
Case Age Sex
 Infectious Underlying Acquired Intravascular 
Antibiotics Ref.
   foci conditions source devices
 1 39 yr M Meningitis Epilepsy Community – INH, RIF, SM 3
 2 79 yr M Pneumonia Pulmonary Hospital – Ampicillin 4
    embolization, Af
 3 61 yr M SSTI Aorto-bifemoral  Hospital Dacron graft Cephalothin,  9
    bypass, alcoholism,    erythromycin,
    narcotic abuse   tobramycin
 4 72 yr F Pneumonia COPD, steroid use Community – Cefotaxime, amikacin 10
 5 82 yr M Primary ESRD Community – Vancomycin, amikacin 11
 6 47 yr M Primary LC, alcoholism Community – Cefotaxime, tobramycin 12
 7 6 yr M Primary None Community – Cefotaxime, gentamicin 12
 8 30 yr F Primary AIDS Community Groshong catheter Ceftazidime, amikacin 13
 9 67 yr M Primary Bladder carcinoma Community Groshong catheter Ceftazidime, TMP/SMZ 13
10c 64 yr F Primary Alcoholism, burn Hospital Intravascular catheterd Ceftazidime, ceftizoxime 14
11 51 yr M CR-BSI Multiple myeloma,  Hospital Hickman catheter Imipenem, amoxicillin/ 15
    PBSCT   clavulanate
12 21 yr M CR-BSI NHL, PBSCT Hospital Hickman catheter Imipenem, amikacin,  15
       ceftazidime, ciprofloxacin
13 44 yr F CR-BSI Perforated appendicitis Hospital CVC Ampicillin, gentamicin,  16
       ciprofloxacin
14 –a F –b Breast cancer, PBSCT Hospital Intravascular catheterd Fluoroquinolone 17
15 –a F –b Breast cancer, PBSCT Hospital Intravascular catheterd Fluoroquinolone 17
16 –a M –b Multiple myeloma,  Hospital Intravascular catheterd Fluoroquinolone 17
    PBSCT
17 –a M –b Lymphoma, PBSCT Hospital Intravascular catheterd Fluoroquinolone 17
18 48 yr M BTI Cholangiocarcinoma Hospital None N/A 18
19 10 d M CR-BSI Prematurity, respiratory Hospital Arterial-line N/A 18
    distress
20 78 yr F CR-BSI Ovarian cancer, C/T Hospital Port-A-Cath N/A 18
21 57 yr F CR-BSI ALL, C/T Hospital Chemo-Cath Piperacillin, ceftazidime, 19
       netilmicin
22c 14 yr M CR-BSI AML, BMT Hospital CVC Piperacillin-tazobactam, 20
       meropenem, gentamicin
23 11 yr M Primary NHL, C/T Hospital Hickman catheter Imipenem 21
24 3 yr M Primary AML, BMT Hospital Hickman catheter Imipenem 21
25 6 yr F Primary Lymphoma, C/T Hospital Hickman catheter Imipenem 21
26 5 yr F Primary Neuroblastoma, C/T Hospital Hickman catheter Imipenem 21
aAges ranged from 22 to 51 years; bdefinite catheter-related infections in two cases, and possible catheter-related infections in two cases; cpatient 
survived but with septic shock; dunknown type of intravascular catheters. INH = isoniazid; RIF = rifampin; SM = streptomycin; SSTI = skin and 
soft tissue infection; Af = atrial fibrillation; COPD = chronic obstructive pulmonary disease; ESRD = end-stage renal disease; LC = liver cirrhosis; 
AIDS = acquired immunodeficiency disease; TMP/SMZ = trimethoprim/sulfamethoxazole; CR-BSI = catheter-related bloodstream infection; 
PBSCT = peripheral blood stem cell transplantation; NHL = non-Hodgkin’s lymphoma; CVC = central venous catheter; BTI = biliary tract infection; 
N/A = not available; C/T = chemotherapy; ALL = acute lymphocytic leukemia; AML = acute myelocytic anemia; BMT = bone marrow transplantation.
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16 from 1991 to 2000, and six were reported after 2001 
(Figure).
Combining cases from our patients with those from 
the literature, we found a total of 42 patients with positive 
blood cultures for S. paucimobilis. The median age was 
48.5 years (range, 10 days–87 years) and 57.1% were male 
(Table 3). Hospital-acquired bacteremia was identified in 
69.0% of these patients (62.5% in our hospital and 73.1% 
in the literature). Of the 42 patients, 25 (59.5%) had ind-
welling intravenous devices. The most common comor-
bidities of these patients were malignancy (57.1%), 
followed by immunosuppressant use (40.5%). Other co-
morbidities included diabetes mellitus (11.9%), alcohol-
ism (9.5%), liver cirrhosis (9.5%), end-stage renal disease 
(7.1%), chronic obstructive pulmonary disease (4.8%), 
burn injury (2.4%), and acquired immunodeficiency syn-
drome (2.4%). Primary S. paucimobilis bacteremia was 
found in 35.7% of patients. Catheter-related bloodstream 
infection was identified in 33.3% of patients, skin and soft 
tissue infection in 9.5%, pneumonia in 9.5%, urinary tract 
infection in 4.8%, biliary tract infection in 4.8%, and men-
ingitis in 2.4%.
The antimicrobial susceptibility of blood isolates of 
S. paucimobilis from our hospital is summarized in Table 4. 
The most active antimicrobial agents were levofloxacin 
(92.9%, 13/14) ciprofloxacin (81.3%, 13/16), ampicillin/
sulbactam (81.3%, 13/16), piperacillin/tazobactam (81.3%, 
13/16), and imipenem (81.3%, 13/16). Aminoglycosides (gen-
tamicin, amikacin) were also effective against S. paucimobilis 
(75.0%, 12/16). Patients with S. paucimobilis bacteremia 
received diverse antibiotic treatments. Most patients in 
our hospital received first-, second-, or third-generation 
cephalosporins, amoxicillin/ampicillin with clavulanate/
sulbactam, or piperacillin, combined with or without 
aminoglycosides. In addition, treatment with fluoroqui-
nolones or carbapenems was also reported in the litera-
ture. Of the 16 patients in our hospital, six (37.5%) received 
inappropriate initial empirical antibiotic therapy. The 
majority of patients, including those receiving inappro-
priate initial empirical antibiotic treatment at our hospi-
tal and patients from the literature, recovered from 
S. paucimobilis bacteremia. However, three patients (7.4%) 
suffered septic shock, including one patient from our 
hospital and two patients from the literature.
Discussion
S. paucimobilis was initially implicated as the causative 
pathogen in an infectious leg ulcer,2 but until recently was 
rarely encountered in clinical settings. However, sporadic 
case reports indicate that the incidence of infection 
has been increasing in recent years, and our hospital has 
identified 16 cases of S. paucimobilis bacteremia in the past 
4 years. This suggests that S. paucimobilis may be an emerg-
ing infectious pathogen worthy of further attention.
S. paucimobilis has been isolated from both natural and 
hospital environments.5–8 This ubiquitous distribution im-
plicates S. paucimobilis in both hospital- and community-
based infections. Hospital-acquired infections accounted 
for 69.0% of patients with S. paucimobilis bacteremia in our 
survey. Most of these patients acquired the infection in 
the hospital setting secondary to the presence of indwell-
ing intravascular devices. The nosocomial infections are 
similar to those caused by non-enteric Gram-negative ba-
cilli from hospital water distribution systems which may 
result in severe infections in patients with underlying de-
bilitating conditions or with indwelling devices.31 Recur-
rent and cluster infections have also been reported.19,21 In 
our study, we did not type these strains so cannot be sure 
whether our patients represent an outbreak of a single 
clone. However, these hospital-acquired bacteremias oc-
curred in different wards and at different times and we 
therefore propose that these infections are not part of a 
single outbreak.
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Figure. Number of reported cases of S. paucimobilis bacteremia.
aInclude the 16 patients in the present study.
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Bacteremia caused by Gram-negative bacteria fre-
quently results in significant morbidity and mortality 
rates, especially in patients with nosocomial infections. 
However, S. paucimobilis strains have not been strongly as-
sociated with high morbidity or mortality. This survey 
revealed no deaths due to S. paucimobilis bacteremia, 
but three patients went into septic shock as a result of 
S. paucimobilis bacteremia. Several factors might contrib-
ute to the virulence of S. paucimobilis in human infections. 
This organism was found to have a significantly different 
enzyme profile from that of other bacteria, which may 
contribute to its pathogenesis.32 Additionally, the pres-
ence of atypical lipopolysaccharide constituents of the 
outer cellular membrane of S. paucimobilis that may corre-
spond to the lipid A present in other Gram-negative bac-
teria, with the accompanying deficiency in endotoxin 
activity, has been proposed to explain the low virulence of 
S. paucimobilis.33 Although S. paucimobilis may be considered 
Table 3. Demographic characteristics and clinical features among patients with Sphingomonas paucimobilis bacteremiaa
Characteristics Present study (n = 16) Literature (n = 26) Total (n = 42)
Age 54.0 yr (5 mo–87 yr) 45.5 yr (10 d–82 yr)b 48.5 yr (10 d–87 yr)c
Sex
  male 8 (50.0) 16 (61.5) 24 (57.1)
  female 8 (50.0) 10 (39.5) 18 (42.9)
Acquired source
  Hospital 10 (62.5) 19 (73.1) 29 (69.0)
  Intravascular devices 6 (37.5) 19 (73.1) 25 (59.5)
Underlying conditions
  Malignancy 9 (56.3) 15 (57.7) 24 (57.1)
  Solid 9 (56.3) 6 (23.1) 15 (35.7)
  Hematologic 0 (0) 9 (34.6) 9 (21.4)
  DM 5 (31.3) 0 (0) 5 (11.9)
  ESRD 2 (12.5) 1 (3.8) 3 (7.1)
  COPD 1 (6.3) 1 (3.8) 2 (4.8)
  Alcoholism 1 (6.3) 3 (11.5) 4 (9.5)
  Liver cirrhosis 3 (18.8) 1 (3.8) 4 (9.5)
  AIDS 0 (0) 1 (3.8) 1 (2.4)
  Burn injury 0 (0) 1 (3.8) 1 (2.4)
  Immunosuppressant use 3 (18.8) 14 (53.8) 17 (40.5)
  Chronic use of steroid 3 (18.8) 1 (3.8) 4 (9.5)
  BMTd 0 (0) 8 (30.8) 8 (19.0)
  Chemotherapy 0 (0) 5 (19.2) 5 (11.9)
Infectious foci
  CR-BSI 3 (18.8) 11 (42.3) 14 (33.3)
  SSTI 3 (18.8) 1 (3.8) 4 (9.5)
  BTI 1 (6.3) 1 (3.8) 2 (4.8)
  UTI 2 (12.5) 0 (0) 2 (4.8)
  Pneumonia 2 (12.5) 2 (7.7) 4 (9.5)
  Meningitis 0 (0) 1 (3.8) 1 (2.4)
  Primary 5 (31.3) 10 (38.5) 15 (35.7)
aData presented as median (range) or n (%); bdata from 22 patients; cdata from 38 patients; dincluding two patients with bone marrow trans-
plantation and six patients with peripheral blood stem cell transplantation. DM = diabetes mellitus; ESRD = end-stage renal disease; 
COPD = chronic obstructive pulmonary disease; AIDS = acquired immunodeficiency syndrome; BMT = bone marrow transplantation; 
CR-BSI = catheter-related bloodstream infection; SSTI = skin and soft tissue infection; BTI = biliary tract infection; UTI = urinary tract infection.
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to have low virulence, it can still cause life-threatening 
septic shock, especially in immunocompromised hosts.
No standard method currently exists to determine the 
antibiotic susceptibility of S. paucimobilis and these data 
are therefore variable in the literature. Peel et al stated that 
the isolate of S. paucimobilis from a leg ulcer was susceptible 
to tetracycline, kanamycin, gentamicin, sulfamethoxazole, 
chloramphenicol, carbenicillin, and tobramycin, but re-
sistant to ampicillin, cephalothin, streptomycin, and col-
istin, as determined by a disk diffusion method.2 Slotnick 
et al used disk agar-diffusion testing and revealed that their 
isolates were sensitive to ampicillin, carben icillin, chlo-
ramphenicol, gentamicin, tobramycin, kana mycin, tetra-
cycline, and cotrimoxazole, and resistant to cephalothin, 
polymyxin, and nalidixic acid.4 Smalley et al determined 
antimicrobial susceptibility by a microbroth dilution 
method34 and they reported that all of the isolated S. pau-
cimobilis strains produced β-lactamase and were therefore 
resistant to the majority of cephalosporins and penicillins. 
Reina et al evaluated the minimal inhibitory concentra-
tion of four isolates and observed that all were susceptible 
to ciprofloxacin and norfloxacin, and they concluded that 
aminoglycosides and fluoroquinolones should be the 
clinical antibiotics of choice for S. paucimobilis infection 
in humans.12 Recently, Kilic et al determined the suscepti-
bility of S. paucimobilis to eight antimicrobial agents by 
E-test (AB BIODISK, Solna, Sweden) and found that all 
isolates were susceptible to trimethoprim-sulfamethoxazole, 
imipenem, meropenem, amikacin, cefotaxime, and 
piperacillin-tazobactam, but 33.3% (2/6 isolates) were re-
sistant to ciprofloxacin and gentamicin.21 The most effective 
antimicrobial agents for S. paucimobilis isolates in vitro in 
our patients were fluoroquinolones, β-lactam/β-lactamase 
inhibitor combinations, carbapenems, and aminoglyco-
sides. Most of our patients received first- second-,or third 
generation cephalosporins or amoxicillin/ampicillin (with 
or without clavulanate/sulbactam), either combined with 
aminoglycosides or not, and they all survived S. paucimobilis 
infection, even after receiving inappropriate initial em-
pirical antibiotics. The favorable outcome in our study 
may support the conclusion that S. paucimobilis has low 
virulence.
There are several limitations in our study. First of all, 
this is a retrospective study. The treatments administered 
depended on the physicians’ choice. Although all patients 
survived, it is difficult to compare the effect of different 
antibiotic treatments. Moreover, since there are no inter-
pretative standards for S. paucimobilis, a disk diffusion assay 
may not be reliable in determining susceptibility and as a 
treatment guide.
In conclusion, S. paucimobilis can cause a variety of 
infections in healthy as well as immunocompromised 
individuals. The prevalence of S. paucimobilis infection in 
humans seems to have increased in recent times. This or-
ganism is commonly associated with nosocomial infec-
tion, especially in patients with indwelling intravascular 
devices. Although S. paucimobilis is an organism of low 
clinical virulence, infection caused by this pathogen can 
lead to septic shock, particularly in immunocompromised 
patients. Therefore, its importance cannot be neglected. 
Further clinical research is required to characterize this 
increasingly frequent infection.
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